Lead Product(s) : Dafsolimab Setaritox,Grisnilimab Setaritox
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Philikos Begins Phase 1/2 Study of T-Guard® in Patients with Systemic Sclerosis
Details : T-Guard is designed to rapidly and safely reset the body’s immune system in life-threatening T-cell mediated conditions such as severe autoimmune diseases.
Product Name : T-Guard
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
May 20, 2025
Lead Product(s) : Dafsolimab Setaritox,Grisnilimab Setaritox
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : XZ.700
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : $24.5 million
Deal Type : Financing
Micreos’ Alternative to Antibiotics Secures Next €25 Million
Details : Proceeds includes the clinical development of XZ.700 for endolysins against staphylococci (including MRSA) for Bloodstream Infections, Atopic Dermatitis, Diabetic Foot Ulcers and Cutaneous T-cell Lymphoma, a type of skin cancer associated with presence o...
Product Name : XZ.700
Product Type : Enzyme
Upfront Cash : Undisclosed
October 25, 2022
Lead Product(s) : XZ.700
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : $24.5 million
Deal Type : Financing
Lead Product(s) : XZ.700
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : $37.1 million
Deal Type : Funding
Details : This funding round will help Micreos accelerate its clinical development programs for atopic dermatitis, diabetic (MRSA) wounds and bloodstream infections, based on its pharmaceutical lead compounds, XZ.700 and SP.800.
Product Name : XZ.700
Product Type : Enzyme
Upfront Cash : Undisclosed
September 30, 2021
Lead Product(s) : XZ.700
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : $37.1 million
Deal Type : Funding
Lead Product(s) : XZ.700
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Micreos Human Health has enrolled the first patients in a Phase I/IIa, randomized, double-blind, placebo-controlled, parallel treated dose-ranging study to assess the safety and efficacy of XZ.700 in patients with mild to moderate atopic dermatitis.
Product Name : XZ.700
Product Type : Enzyme
Upfront Cash : Inapplicable
September 22, 2020
Lead Product(s) : XZ.700
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable